ACHV
NASDAQ HealthcareAchieve Life Sciences, Inc. - Common Shares
Biotechnology
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
๐ Market Data
| Price | $5.03 |
|---|---|
| Volume | 855,159 |
| Market Cap | 516.38M |
| Beta | 2.250 |
| RSI (14-Day) | 34.2 |
| 200-Day MA | $4.18 |
| 50-Day MA | $4.24 |
| 52-Week High | $6.15 |
| 52-Week Low | $2.00 |
| Forward P/E | -10.85 |
| Price / Book | 25.02 |
๐ฏ Investment Strategy Scores
ACHV scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (97/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (4/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ACHV in your text
Paste any article, transcript, or post โ the tool will extract ACHV and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-06-02.